Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.
G1 Therapeutics has appointed Andrew Perry as the new Chief Commercial Officer, succeeding Soma Gupta. This change is part of the company's strategy to enhance the launch of COSELA™ (trilaciclib) in extensive-stage small cell lung cancer. Perry brings nearly 25 years of experience in product commercialization and has a strong background in oncology. Additionally, the company has granted Perry a stock option to purchase 300,000 shares, enhancing his commitment to G1 Therapeutics. This leadership transition aims to further optimize the operational execution and commercial success of its product line.
G1 Therapeutics (GTHX) will host a webcast and conference call on August 4, 2021, at 4:30 p.m. ET to discuss its second-quarter 2021 corporate and financial update. The call can be accessed via phone or through their Events & Presentations page. G1 Therapeutics is focused on developing therapies for cancer, including their product, COSELA™ (trilaciclib), with ongoing clinical evaluations in various solid tumors. The company is based in Research Triangle Park, N.C.
G1 Therapeutics, Inc. (GTHX) announced that the FDA granted Fast Track designation for COSELA™ (trilaciclib) in treating locally advanced or metastatic triple negative breast cancer (TNBC). This designation is aimed at expediting drug development and regulatory review, potentially leading to earlier patient access. COSELA is being tested in a pivotal Phase 3 trial (PRESERVE 2) alongside chemotherapy for TNBC, a notably aggressive cancer representing 15-20% of breast cancer cases. The company aims to enhance patient outcomes with this innovative treatment.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for 80,400 shares to eight new employees under its 2021 Inducement Equity Incentive Plan. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and incentivizes new hires. Options are priced at $22.47, reflecting the closing price on July 1, 2021, and vest over four years. G1 focuses on oncology, including the commercialization of COSELA™ and a range of clinical developments targeting various solid tumors.
G1 Therapeutics (GTHX) announced the appointment of Alicia Secor to its Board of Directors, enhancing its strategic leadership. With over 30 years in the life sciences sector, Secor has a proven history of guiding companies through product commercialization. Currently CEO of Atalanta Therapeutics, she emphasizes her commitment to maximizing the value of COSELA™ and improving patient access. CEO Jack Bailey highlighted Secor’s experience and vision as crucial for G1’s future growth. Secor's prior roles include leadership positions at Juniper Pharmaceuticals and Genzyme.
G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference on June 22 at 9:20 AM EDT. The virtual event will include a fireside chat, accessible via a live webcast on G1's website. G1 Therapeutics specializes in developing therapies for cancer patients, including their first product, COSELA™ (trilaciclib), which is being evaluated in various solid tumors like colorectal, breast, lung, and bladder cancers. For more details, visit their website.
G1 Therapeutics has initiated PRESERVE 3, a Phase 2 study to evaluate COSELA (trilaciclib) combined with platinum-based chemotherapy and avelumab for treating metastatic urothelial carcinoma (mUC). The randomized trial aims to enroll 90 patients, assessing the safety, efficacy, and myeloprotection of COSELA. Initial results are expected in late 2022, with endpoints focused on progression-free survival and overall survival. The study addresses the stagnant five-year survival rate for mUC, highlighting a significant unmet need in this area.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for a total of 44,200 shares to five new employees as part of its 2021 Inducement Equity Incentive Plan. These options are exercisable at $21.93 per share, the closing price on the grant date of June 1, 2021. Each option vests over four years, with 25% vesting after the first year. The plan is designed to attract new talent by granting equity awards to individuals who were not previously employed by G1, in compliance with Nasdaq rules.
G1 Therapeutics, Inc. (GTHX) reported positive results from its Phase 1 study of rintodestrant, an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2- advanced breast cancer. The combination treatment demonstrated a significant increase in the clinical benefit rate, rising from 30% with rintodestrant alone to 60% with the combination. The treatment was well tolerated, with no serious adverse events reported. The study suggests potential effectiveness, especially in patients with ESR1 variants, further warranting clinical evaluation.
G1 Therapeutics (GTHX) presented positive results from analyses of COSELA (trilaciclib) during the ASCO annual meeting, focusing on its immune effects in extensive-stage small cell lung cancer (ES-SCLC) patients. Analyses from two Phase 2 trials revealed that patients receiving COSELA showed significantly greater peripheral T-cell clonal expansion compared to placebo recipients. Results indicate a potential link between peripheral clonal expansion and clinical response. The company also highlighted ongoing Phase 3 trials for COSELA in triple-negative breast cancer.